Organic Active Ingredients TRIZ Cases

Genome editing system generates blunt-ended DNA breaks to excise intron segments and restore functional donor splice sites.

Porous silicon particles enable sustained intraocular drug delivery through diffusion and degradation, eliminating frequent invasive injections.

Aryl analogs modulate the NRF2 pathway to address inadequate oxidative stress management, slowing disease progression in COPD and asthma.

Incorporating bicyclic amino acid residues into inhibitor structures enhances oral bioavailability while maintaining specific Cathepsin C inhibition.

BET, IKK, JAK, PDK1, and Syk inhibitors maintain T cells in less differentiated states during ex vivo expansion to improve therapeutic efficacy.

ASO-mediated depletion of lnc-HLX-2-7 reduces proliferation and induces apoptosis, resolving side effects from conventional therapies.

Aceclidine formulation resolves presbyopia treatment contradictions by improving depth of focus while minimizing distance blur and retinal detachment risks.

A hypocaloric tube feed formulation combines multiple protein sources with processed whole foods to deliver complete nutrition.

Inhibiting HIF prolyl hydroxylases increases endogenous erythropoietin production, treating anemia without exogenous therapy risks.

Developing cyclic compounds that block TLR4 signaling resolves the lack of effective inhibitors for chemotherapy-induced peripheral neuropathy.

Esterifying tocotrienols with nicotinic acid improves stability and bioavailability in cosmetic formulations.

Ginseng extract reduces metal ions to nanoparticles and stabilizes the surface, eliminating costly chemical agents.

Novel benzoic acid derivatives modify terminal groups to enhance metabolic stability and reduce toxicity in pharmaceutical applications.

Hydrophobic polymer coating prevents alcohol-induced dose dumping in sustained-release oral pharmaceutical forms.

Indoline compounds selectively inhibit HDAC6 while activating Nrf2 and HIF to treat neurological disorders with reduced side effects.

Optimizing phospholipid and surfactant concentrations creates homogeneous, stable foams that resolve development time bottlenecks in topical drug formulation.

Autophagy and DCAR-1 inhibitors overcome drug resistance by blocking parasite recovery.

BO-110 polycationic complexes protect unstable dsRNA from degradation while selectively killing melanoma cells via dual autophagy and apoptosis induction.

Characterizing novel Riociguat polymorphs resolves stability issues, enabling reliable drug formulation.

Crystallization inhibitors prevent active agent crystallization in medical adhesives, ensuring predictable drug release while preserving adhesive tack.

Selective PAR-4 antagonists reduce bleeding risks while maintaining antithrombotic efficacy in thromboembolic disorders.

Modified compounds overcome poor brain penetration of current therapies, enhancing CNS concentration and therapeutic efficacy.

CAP7.1 prodrugs bypass ABC transporter resistance to kill cancer stem cells and prevent tumor relapse.

TG02 polymorphs inhibit CDKs, JAK2, and FLT3 simultaneously, overcoming limited efficacy of single-target kinase inhibitors.

Antibody-drug conjugates deliver exatecan payloads via cathepsin B cleavable linkers to cancer cells.

Tricyclic fused thiophene derivatives modulate Janus kinase activity through specific structural substitution patterns.

Adjusting formulation parameters to basic pH and low water content resolves the solubility stability contradiction while reducing urothelial toxicity.

Replacing immunogenic antibodies with small molecule targeting groups eliminates tolerance issues while sustaining long-term tumor growth inhibition.

A biotin moiety conjugates to physiologically active substances to enhance oral absorption via sodium-dependent multivitamin transporters.

Antisense oligonucleotides inhibit miR-27a and miR-182 clusters, reducing fibrosis caused by bile acid toxicity in cholestasis.

Montbretin A inhibits human pancreatic alpha-amylase through specific binding, reducing postprandial glucose spikes without gastrointestinal side effects.

Administering hepatocyte growth factor nucleic acid sequences prior to surgery resolves revascularization inefficiency and improves skin flap survival rates.

Biaryl cyclohexene compounds inhibit CETP to raise HDL-C and lower LDL-C, avoiding blood pressure spikes linked to prior inhibitors.

A pharmaceutical coating uses segmented cationic and anionic polymer layers to control active substance release rates through pH-dependent swelling.

Transitioning to crystalline Form III prevents polymorphic changes while preserving dissolution properties.

1H-pyrazolo[4,3-H]quinazoline compounds inhibit cyclin-dependent kinases with enhanced metabolic stability.

Phenylglyoxaldehyde sorbent binds urea at 1.60 mmol/g, enabling compact dialysis devices without harmful byproducts.

Pre-screening for HLA-DQA1*0201, HLA-DQB1*0202, and HLA-DRB1*0701 prevents hepatotoxicity while maintaining therapeutic efficacy.

A glycosaminoglycan derivative couples a physiologically active substance via a covalent spacer bond to enable controlled drug release.

Fourth-generation heterocyclic inhibitors target triple mutant EGFR variants, overcoming resistance while maintaining favorable toxicity profiles.

A Croton lechleri hydrogel formulation delivers broad-spectrum antimicrobial activity against skin pathogens.

Computer-aided virtual screening identifies small molecule flavonoids that disrupt IL-17A-IL-17RA interaction, replacing costly monoclonal antibodies.